Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F13%3A10209592" target="_blank" >RIV/00064203:_____/13:10209592 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/13:10209592

Result on the web

<a href="http://dx.doi.org/10.1182/blood-2013-02-484097" target="_blank" >http://dx.doi.org/10.1182/blood-2013-02-484097</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2013-02-484097" target="_blank" >10.1182/blood-2013-02-484097</a>

Result language

angličtina

Original language name

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004

Original language description

Outcomes of patients with acute myeloid leukemia (AML) improve significantly by intensification of induction. To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2) per day for 3 days) during induction. In the multicenter therapy-optimization trial AML-BFM 2004, 521 of 611 pediatric patients (85%) were randomly assigned to L-DNR or idarubicin induction. Five-year results in both treatment arms were similar (overall survival 76% +/- 3% [L-DNR] vs 75% +/- 3% [idarubicin], P-logrank = .65; event-free survival [EFS] 59% +/- 3% vs 53% +/- 3%, P-logrank = .25; cumulative incidence of relapse 29% +/- 3%vs 31% +/- 3%, P-(Gray) = .75), as were EFS results for standard (72% +/- 5% vs 68% +/- 5%, P-logrank = .47) and high-risk (51% +/- 4% vs 46% +/- 4%, P-logrank = .45) patients. L-DNR resulted in significantly better probability of EFS in

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

122

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

37-43

UT code for WoS article

000321909300009

EID of the result in the Scopus database

—